Skip to main content
C

Charmacy Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 2289 HKEX Wholesale and retail trade
Open in API
Filings indexed 509 across all filing types
Latest filing 2025-11-06 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2289

About Charmacy Pharmaceutical Co., Ltd.

http://www.chmyy.com

Charmacy Pharmaceutical Co., Ltd. is a leading pharmaceutical distribution company operating primarily in Southern China (Guangdong, Fujian, Guangxi, and Hainan). The core business involves distributing a comprehensive range of products, including Western medicines, Chinese patent medicines, and healthcare products, primarily targeting downstream distributors and retail terminal customers (chemists). The company specializes in the non-tender pharmaceutical market, where it holds a leading position. Additionally, Charmacy provides value-added services such as third-party logistics (3PL) and pharmaceutical product consultation, supported by modern distribution centers in key cities like Shantou, Guangzhou, and Shenzhen.

Recent filings

Filing Released Lang Actions
PROPOSED CHANGE OF AUDITORS
Regulatory Filings Classification · 1% confidence The document is an official announcement regarding the 'Proposed Change of Auditors' for Charmacy Pharmaceutical Co., Ltd. It details the resignation of the current auditor (ShineWing) and the proposed appointment of a new auditor (Pan-China), citing regulatory compliance with the Administrative Measures for Selection and Appointment of Accounting Firms. This type of corporate governance announcement, which does not fit into specific categories like financial reports or director dealings, is best classified as a general regulatory filing.
2025-11-06 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2025
Regulatory Filings Classification · 1% confidence The document is a monthly regulatory return (Form FF301) submitted to the Hong Kong Exchange under Chapter 19B Listing Rules, detailing movements in authorized, issued, and treasury shares. It is not announcing a specific share issuance, dividend, or financial results, nor is it the annual or interim report itself. It is a routine regulatory filing with no substantive capital change. Therefore it best fits the fallback category for general regulatory filings under exchange rules.
2025-11-03 English
(1)PROPOSED ABOLISHMENT OF THE BOARD OF SUPERVISORS&#x3b; AND (2)PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND THE RELATED CORPORATE GOVERNANCE POLICIES
Regulatory Filings Classification · 1% confidence The document is an announcement made under Rule 13.51(1) of the Hong Kong Listing Rules, notifying shareholders of proposed corporate governance changes (abolishment of the Board of Supervisors and amendments to the Articles of Association) to be considered at an extraordinary general meeting. It is not the full governance report or proxy circular itself, but a regulatory announcement of proposals under the Listing Rules, so it falls into the general Regulatory Filings category (RNS).
2025-10-20 English
RENEWAL OF CONTINUING CONNECTED TRANSACTIONS IN RELATION TO FRAMEWORK LOAN AGREEMENT
Capital/Financing Update Classification · 1% confidence The document is a Hong Kong Stock Exchange announcement regarding the renewal of a continuing connected transaction in the form of a new three-year framework loan agreement with a controlling shareholder. It is focused on the company’s financing arrangements (loan facility terms, annual caps, internal controls) rather than reporting financial results or board changes. This falls squarely under “Updates on company fundraising, financing activities, or capital structure changes.”
2025-10-20 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2025
Regulatory Filings Classification · 1% confidence The document is a FF301 form submitted to the Hong Kong Exchanges and Clearing Limited detailing the monthly return of equity issuer share capital movements under Chapter 19B of the Exchange Listing Rules. It is neither an earnings release nor an annual/interim report, nor a board change, dividend notice, M&A announcement, or specific share issuance event. Instead, it is a routine regulatory compliance filing of monthly share movement data. Since it does not fall into any specific category like share issue, repurchase or capital change announcements, it defaults to the general “Regulatory Filings” category.
2025-10-02 English
2025 INTERIM REPORT
Interim / Quarterly Report Classification · 1% confidence The document is titled '2025 中期報告' (2025 Interim Report) and contains comprehensive financial statements, management discussion and analysis, and corporate information for the six-month period ended June 30, 2025. It is a formal, substantive financial report rather than an announcement or a summary, fitting the definition of an Interim/Quarterly Report. H1 2025
2025-09-29 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.